Comments
Commented by André Will-Laudien on May 5th, 2025 | 07:20 CEST
Biotech is back with artificial intelligence! Evotec, NetraMark Holdings, Bayer, and BioNTech
Artificial intelligence has arrived in health research! Whenever large volumes of data need to be analyzed, patterns recognized, or results condensed, immense computing power is required. The goal is to detect complex structures, automate processes, and make real-time decisions. The use of AI in medicine and pharmaceutical development is making good progress because time and high validation capability are key here. Some companies have already recognized the signs of the times and are working hard on the new technologies. On the stock market, this is often the starting signal for significantly higher valuations. Evotec, Bayer, and BioNTech are well-known European players, while Canadian company NetraMark Holdings has seen its share price increase sevenfold since fall 2024. What is behind this surge?
Read
Commented by Armin Schulz on May 5th, 2025 | 07:15 CEST
How Palantir, MiMedia Holdings, and SAP are transforming the cloud into trillion-dollar markets
The cloud is the invisible titan of the digital economy. It drives innovation, breaks efficiency barriers, and is expected to generate over USD 800 billion in 2025 alone. But behind the scenes, tech pioneers are shaping the rules of this billion-dollar market. With AI-driven forecasts, disruptive data storage solutions, and cloud-based ecosystems, they are deciding who will dominate the era of hyperdigitalization. While companies are fiercely competing for agility and scale in the race for the cloud strategies of the future, three players are setting the standard with technologies that are changing not only markets but also mindsets. A look at Palantir, MiMedia Holdings, and SAP reveals what makes them different from the rest.
Read
Commented by Nico Popp on May 5th, 2025 | 07:10 CEST
Lithium Made in Europe: European Lithium, SQM, Stellantis, and the supply chains of the future
Electromobility is booming - but without lithium, there are no batteries, and without batteries, there is no mobility transition. While major corporations like SQM from Chile dominate the market, European Lithium is working to make Europe more independent. At the same time, manufacturers such as Stellantis are establishing local supply chains to decouple themselves from global supply risks. We outline the situation in the lithium market and take a European perspective.
Read
Commented by Stefan Feulner on May 5th, 2025 | 07:05 CEST
Nel ASA, First Hydrogen, BYD – Warren Buffett steps down and significant rebound opportunities
The bombshell dropped over the weekend! The Oracle of Omaha is stepping down and passing the baton. With cash reserves of USD 347.7 billion, Berkshire Hathaway's rejuvenated management is entering a new era. In addition to this breaking news, the past trading week saw a flurry of quarterly figures. Several companies in the renewable energy sector once again failed to meet expectations. However, there are opportunities for a rebound, albeit at significantly reduced levels.
Read
Commented by Fabian Lorenz on May 5th, 2025 | 07:00 CEST
NEW PRICE TARGET: RENK, Novo Nordisk, and takeover candidate BioNxt Solutions
Analysts are raising their price target for RENK shares significantly. However, they appear to be trailing the current share price. Things will likely get exciting at RENK on May 15, when fresh figures and, hopefully, a well-filled order book will be reported. BioNxt Solutions shares are currently of interest. Clinical trials are about to begin on the development of the leading product for the easier treatment of multiple sclerosis. The stock is cheap and seen as a hot takeover candidate - perhaps for Novo Nordisk? With simplified administration, the Danes could further accelerate sales of Ozempic and potentially reduce costs. The stock is working on a bottom, and analysts recommend it as a "Buy".
Read
Commented by Armin Schulz on May 2nd, 2025 | 07:00 CEST
Military, precious metals, AI technology: Why RENK Group, Golden Cariboo Resources, and Super Micro Computer are booming right now
2025 is shaping up to be a year of superlatives. The defense industry, gold market, and AI technology are all experiencing an unprecedented boom. While conflicts and arms races are causing demand for high-tech military solutions to skyrocket - with German defense giants recording double-digit growth rates - gold prices are soaring to record highs. Investors are fleeing to the safe haven of precious metals in the face of geopolitical turmoil and inflation. At the same time, AI is not only driving consumer goods but also revolutionizing security strategies and data infrastructure. We take a look at an exciting company from each of these sectors.
Read
Commented by Fabian Lorenz on May 1st, 2025 | 07:10 CEST
A bombshell at Nel ASA! Buying opportunity for Bayer and Defence Therapeutics shares?
A bombshell at Nel ASA. The hydrogen specialist has reported its first quarter results: revenue and order intake are down, while the Company is sliding deep into the red. Will new major shareholder Samsung bring about a turnaround? Defence Therapeutics is a hot rebound candidate with takeover speculation. The biotech company is consistently pushing ahead with the monetization of its technology and has found a strong partner. The decline in the share price in recent months offers opportunities. A lot of negative news is certainly already priced into Bayer's share price, but is that enough to buy the stock? Yes, according to analysts.
Read
Commented by Armin Schulz on May 1st, 2025 | 07:05 CEST
AI race in a billion-dollar market: How are Evotec, NetraMark Holdings, and Novo Nordisk doing in the race?
The pharmaceutical industry is undergoing a seismic change! Algorithms are replacing microscopes, and data pools are becoming the new pipeline for therapeutic breakthroughs. As billions are poured into artificial intelligence (AI), the battle is raging to crack the code for the next drug revolution – and to avoid drowning in a sea of data. Innovators like NetraMark are using machine learning to demystify clinical trials, while giants like Novo Nordisk are reinventing diabetes treatments with digital twins. Evotec is using AI-driven approaches to drug discovery. Who will succeed in bridging the gap between hype and healing?
Read
Commented by Nico Popp on May 1st, 2025 | 07:00 CEST
Raw materials for the future: What Power Metallic Mines, Barrick Gold, and Albemarle offer investors
Whether for the energy transition, digitalization, or the infrastructure of tomorrow, the world's hunger for raw materials is growing. Power Metallic Mines, Barrick Gold, and Albemarle are prime examples of tomorrow's raw material suppliers – from classic exploration to specialty metals for the green transformation. The three business models are different, but where do the most significant opportunities lie for investors? We provide new answers!
Read
Commented by Fabian Lorenz on April 30th, 2025 | 07:15 CEST
Buy BioNTech after the crash? Valneva with vaccine problems! Vidac Pharma shares show potential!
BioNTech shares crashed by around 10% on Friday. So far, they have not been able to recover. What caused the setback? Should investors seize the opportunity? Analysts believe the German biotech heavyweight is on track. The same applies to Vidac Pharma. The news flow is extremely positive, but the stock is not making any headway. Analysts believe that Vidac shares could multiply in value. If the biotech company continues to be successful, a takeover could follow. And what is going on at Valneva? The stock is on a rollercoaster ride. Could a vaccine become a problem?
Read